Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TP53 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
TP53 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
BRCA2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BRCA2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
BRCA1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
BRCA1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
PARP2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PARP2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
PARP1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PARP1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
CHEK2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CHEK2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
CHEK1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CHEK1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ATM 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ATM 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ATR 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ATR 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
WEE1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
WEE1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
PLK1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PLK1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
AURKB 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
AURKB 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.